Inivata and Collaborators to Present New Data to Support the Application of RaDaR™ MRD Assay Across Tumor Types at ESMO Congress 2022
September 07, 2022 02:44 ET
|
Inivata
Inivata and Collaborators to Present New Data to Support the Application of RaDaR™ MRD Assay Across Tumor Types at ESMO Congress 2022 Research Triangle Park, NC, USA and Cambridge, UK, 7 September...
Inivata and Collaborators Announce New Data Demonstrating Clinical Potential of its RaDaR™ MRD Test in HR+ HER2- Breast Cancer
June 21, 2022 07:00 ET
|
Inivata
Inivata and Collaborators Announce New Data Demonstrating Clinical Potential of its RaDaR™ MRD Test in HR+ HER2- Breast Cancer Research Triangle Park, NC, USA and Cambridge, UK, 21 June 2022 --...
Inivata and Collaborators to Present New Data Further Validating the Application of its RaDaR® MRD and InVisionFirst®-Lung Tests at the 2022 ASCO Annual Meeting
May 10, 2022 02:00 ET
|
Inivata
Inivata and Collaborators to Present New Data Further Validating the Application of its RaDaR® MRD and InVisionFirst®-Lung Tests at the 2022 ASCO Annual Meeting Research Triangle Park, NC, USA and...
Inivata and Collaborators Publish New Data on RaDaR™ MRD Assay at AACR 2022
April 11, 2022 10:00 ET
|
Inivata
Inivata and Collaborators Publish New Data on RaDaR™ MRD Assay at AACR 2022 Data demonstrates potential of RaDaR to predict clinical response in stage III urothelial cancer Research Triangle...
Inivata and Collaborators Publish Clinical Validation Data for RaDaR™ Assay in Non-Small Cell Lung Cancer
March 17, 2022 03:00 ET
|
Inivata
Inivata and Collaborators Publish Clinical Validation Data for RaDaR™ Assay in Non-Small Cell Lung Cancer Study further highlights potential of RaDaR to stratify patients and improve treatment...
Inivata and Collaborators Publish Positive Results from Prospective Clinical Study of RaDaR™ in Head and Neck Squamous Cell Carcinoma
February 11, 2022 02:00 ET
|
Inivata
Inivata and Collaborators Publish Positive Results from Prospective Clinical Study of RaDaRTM in Head and Neck Squamous Cell Carcinoma RaDaR demonstrated 100% specificity in patients with no...
Inivata Announces RaDaR™ Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program
January 11, 2022 07:00 ET
|
Inivata
Inivata Announces RaDaR™ Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program Research Triangle Park, NC, USA and Cambridge, UK, 11 January 2022 -- Inivata, a leader...
Inivata Appoints David Eberhard MD, PhD as Chief Medical Officer
December 13, 2021 07:00 ET
|
Inivata
Inivata Appoints David Eberhard MD, PhD as Chief Medical Officer Research Triangle Park, NC, USA and Cambridge, UK, 13 December 2021 -- Inivata, a leader in liquid biopsy, today announced the...
Inivata Announces Clinical Collaboration with Princess Margaret Cancer Center for the use of its Liquid Biopsy Assays
October 19, 2021 07:00 ET
|
Inivata
Inivata Announces Clinical Collaboration with Princess Margaret Cancer Center for the use of its Liquid Biopsy Assays Two clinical studies including interventional RaDaR™ study Research Triangle...
Inivata and collaborators to present data that further validate the application of its RaDaR™ MRD and InVisionFirst®-Lung assays at the ESMO Congress 2021
September 09, 2021 07:00 ET
|
Inivata
Inivata and collaborators to present data that further validate the application of its RaDaR™ MRD and InVisionFirst®-Lung assays at the ESMO Congress 2021 Research Triangle Park, NC, USA and...